Supplementary Appendix

Enrollment Criteria
Patient population
The eligible population for the cirrhosis cohort is patients with a MELD score of ≥ 8 (and ≤ 40) with GT-1, -2, -3, -4, -5 or -6 chronic HCV infection. Approximately 60 patients will be enrolled in the cirrhosis cohort, including approximately 48 (80%) GT-1-infected patients and 12 (20%) non-GT-1 patients. The cirrhosis cohort will be capped at approximately 12 (20%) non-GT-1-infected patients. In addition, of the total 60 patients, approximately 48 (80%) patients will be Child-Pugh class A or B. Child-Pugh class C patients will be capped at approximately 12 (20%).
The eligible population for the posttransplant cohort is patients who have received a liver transplant at least 3 months prior to screening and have GT-1, -2, -3, -4, -5 or -6 chronic HCV infection. Approximately 50 patients will be enrolled in the posttransplant cohort. The posttransplant cohort will be capped at approximately 10 (20%) non-GT-1-infected patients.
Inclusion criteria 1) Signed written informed consent a. Freely given informed consent must be obtained from patients prior to clinical trial participation, including informed consent for any screening procedures conducted to establish patient eligibility for the study.
2) Target Population a. Patients must be able to understand and agree to comply with the prescribed dosing regimens and procedures, report for regularly scheduled study visits, and reliably communicate with study personnel about adverse events and concomitant medications. e. Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with RBV and for 6 months post-treatment completion, or per local guidelines, whichever is longer.
Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception.
Highly effective methods of contraception have a failure rate of < 1% per year when used consistently and correctly.
At a minimum, subjects must agree to the use of two methods of contraception, with one method being highly effective and the other method being either highly effective or less effective as listed below:
Highly Effective Methods of Contraception i Male condoms with spermicide
ii Hormonal methods of contraception including combined oral contraceptive pills, vaginal ring, injectables, implants, and intrauterine devices (IUDs) such as Mirena® by male subject's WOCBP partner. Female partners of male subjects participating in the study may use hormone based contraceptives as one of the acceptable methods of contraception since they will not be receiving study drug. WOCBP cannot use hormonal contraception as one of the two methods of contraception because there are no data on the effectiveness of systemic hormonal contraceptives in women taking SOF. However, WOCBP can continue to use hormonal contraceptives, if necessary, in addition to 2 other non-hormonal methods of contraception.
iii Nonhormonal IUDs, such as ParaGard® iv Tubal ligation v Vasectomy vi Complete Abstinence* *Complete abstinence as defined as complete avoidance of heterosexual intercourse and is an acceptable form of contraception for all study drugs. Subjects who choose complete abstinence are not required to use a second method of contraception, but female subjects must continue to have pregnancy tests. Acceptable alternate methods of highly effective contraception must be discussed in the event that the subject chooses to forego complete abstinence. i. Active substance abuse as defined by DSM-IV, Diagnostic Criteria for Drug and Alcohol Abuse, (Appendix 1) which in the opinion of the investigator would make the candidate inappropriate for participation in this study j. Active severe psychiatric disorders including but not limited to, schizophrenia, psychosis, bipolar disorder, post-traumatic stress disorder, mania, etc.
Less Effective Methods of Contraception
k. Inability to tolerate oral medication l. Poor venous access sufficient to preclude participation in study procedures m. Active hospitalization for decompensated liver disease.
3) The following conditions are exclusion criteria for the use of RBV, based on the respective label:
a. History of haemoglobinopathies (eg, thalassemia major or sickle cell anaemia), diagnoses associated with an increased baseline risk for anaemia (eg, spherocytosis), haemolytic anaemia, or diseases in which anaemia would be medically problematic b. History of cardiomyopathy, active unstable coronary artery disease (including angina), ventricular arrhythmia, congestive heart failure (other than fluid overload due to hepatic insufficiency), pulmonary hypertension or other clinically significant cardiac disease c. Historical or current electrocardiogram (ECG) finding indicative of cardiovascular instability, including but not limited to evidence of myocardial ischemia, unstable reentry phenomena, other significant dysrhythmias, and/or uncontrolled hypertension d. History of hypersensitivity to drugs with a similar biochemical structure to RBV e. Any criteria that would exclude the subject from receiving RBV, per the local label. b. Sexually active fertile men whose partners are pregnant at screening are excluded from this study.
7) Prohibited treatments and/or therapies a. HCV treatment-experienced subjects are eligible. All permitted prior anti-HCV therapies must be discontinued or completed at least 12 weeks prior to screening.
i Previous treatment with IFN-alfa, with or without RBV is permitted. Documentation of prior virologic response to treatment is desirable but not strictly required. Subjects who did not complete treatment due to laboratory abnormality or intolerable side effect are eligible
ii Previous exposure to NS3/4 inhibitors including, but not limited to, telaprevir or boceprevir is permitted. Subjects who did not complete treatment due to laboratory abnormality or intolerable side effects are eligible
iii Previous exposure to nucleoside/tide and non-nucleoside inhibitors of NS5B may be permitted (including SOF). Subjects who discontinued previous treatment with SOF due to intolerance of this drug are excluded.
iv Previous exposure to anti-HCV agents in the following drug classes may also be permitted, including but not limited to: cyclophilin inhibitors and inhibitors of microRNA v Previous exposure to NS5A inhibitors is prohibited. c. Any other medical, psychiatric and/or social reason which, in the opinion of the investigator would make the subject inappropriate for the study.
Eligibility criteria for this study have been carefully considered to ensure the safety of the study subjects and that the results of the study can be used. It is imperative that subjects fully meet all eligibility criteria.
Women of Childbearing Potential
Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes. In addition, women under the age of 55 years must have a serum follicle stimulating hormone, (FSH) level > 40 mIU/mL to confirm menopause.
Women treated with hormone replacement therapy, (HRT) are likely to have artificially suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH level. The duration of the washout period is a function of the type of HRT used. The duration of the washout period below are suggested guidelines and the investigators should use their judgment in checking serum FSH levels. If the serum FSH level is > 40 mIU/ml at any time during the washout period, the woman can be considered postmenopausal:
• 1 week minimum for vaginal hormonal products (rings, creams, gels):
• 4 week minimum for transdermal products • 8 week minimum for oral products. Other parenteral products may require washout periods as long as 6 months.
Ribavirin Dosing Guidelines
Ribavirin administration should be managed as shown below. This table is based on recommendations from the ribavirin package insert, and has been modified in accordance with recent guidelines for HCV treatment for this study.
1 As the 
Composite Historical Threshold for Patients With Cirrhosis
Patients to be enrolled in the advanced cirrhosis cohort are expected to be transplant candidates with significantly more advanced liver disease and a correspondingly lower historical threshold in comparison with the wellcompensated cirrhosis patients treated in the Neutrino and HPC3007/C206 trials. 1,2,3 Patients who failed NS3
protease inhibitors were not included in those trials but it would be reasonable to consider them as nonresponders (to pegIFN/ribavirin) with respect to historical SVR. Patients with Child-Pugh B or C disease are not candidates for any interferon-based therapy, so their historical threshold is set at 5%. An overall estimated historical threshold for a potential enrolled population accounting for these reference rates of SVR is presented in the table below. Child-Pugh B or C 50% Not available 5% 2·5%
Overall Historical Threshold
Overall historical threshold SVR rate 41·6% * Based upon the proposed weighting, the historical threshold for SVR in cirrhotic patients with the distribution described above is estimated at 41·6%. Peripheral edema 4 (8) 1 (8) 2 (6) 1 (6) 8 ( Green shading represents improvement in Child-Pugh class from baseline to follow-up; blue shading represents no change; red shading indicates worsening.
Five patients are excluded from this analysis, including 4 who had treatment interrupted for liver transplantation and 1 patient who experienced normalization of INR after discontinuing warfarin during the study period. 
